| Name | aspartate aminotransferase |
|---|---|
| Synonyms | Aspartate Aminotransferase 1; GIG18; GOT 1; GOT1; Aspartate aminotransferase; Glutamate oxaloacetate transaminase 1; Transaminase A; Aspartate aminotransferases… |
| Name | piperonyl butoxide |
|---|---|
| CAS | 5-[[2-(2-butoxyethoxy)ethoxy]methyl]-6-propyl-1,3-benzodioxole |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 6808867 | Clark JD, Hatch RC, Jain AV, Weiss R: Effect of enzyme inducers and inhibitors and precursor and depleter on induced acute aflatoxicosis in rabbits. Am J Vet Res. 1982 Jun;43(6):1027-33. The drugs administered, mean duration of illness (hours), and survival percentage were as follows: controls (saline solution)-85, 50%; phenobarbital (PB)-100, 100%; phenylbutazone-115, 67%; benzoflavone-39, 17%; stanozolol-67, 67%; cobaltous chloride (CoCl2)-46, 67%; piperonyl butoxide (PBO)-88, 100% (CYS)-68, 100%; ethyl -71, 83%. Clinico-pathologic changes included increased serum aspartate aminotransferase (AST) activity by 24 hours and concentration by 48 to 72 hours after was given. |
1(0,0,0,1) | Details |
| 1965745 | Ishiyama H, Ogino K, Shimomura Y, Kanbe T, Hobara T: Hepatotoxicity of diethyldithiocarbamate in rats. Pharmacol Toxicol. 1990 Nov;67(5):426-30. Plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were markedly elevated 24 hr after subcutaneous administration of DDC and histologically, the liver showed submassive necrosis. Desferrioxamine (a chelator of iron) and piperonyl butoxide (an inhibitor of cytochrome P-450) prevented DDC-induced increases of both ALT and TBARS, but GSH did not, DDC hepatotoxicity was not changed by phenobarbital induction. |
1(0,0,0,1) | Details |
| 6807146 | Hatch RC, Clark JD, Jain AV, Mahaffey EA, Weiss R: Effect of some enzyme inducers, fluids, and - on induced acute aflatoxicosis in goats. Am J Vet Res. 1982 Feb;43(2):246-51. These drugs were phenobarbital (PB), phenylbutazone (PBZ), piperonyl butoxide (PRO), benzoflavones, water, and 5% solution (D5W). Clinical signs of toxicosis, serum aspartate aminotransferase activities, serum concentrations, duration of illness, mortality, and gross and microscopic pathologic findings taken together indicated that toxicosis was increased with MET-TS + PB therapy, PBZ pretreatment, PBZ therapy, benzoflavone pretreatment, benzoflavone therapy, MET-TS + benzoflavone therapy, and MET-tS + water therapy. |
1(0,0,0,1) | Details |
| 2392799 | Fukushima K, Arai M, Kohno Y, Suwa T, Satoh T: An epoxysuccinic acid derivative (loxistatin)-induced hepatic injury in rats and hamsters. Toxicol Appl Pharmacol. 1990 Aug;105(1):1-12. The severity of the lesions was dose-dependent up to 200 mg/kg and also manifest by an increase in serum alanine aminotransferase and aspartate aminotransferase activities. Pretreatment with SKF-525A resulted in increased hepatic injury, while pretreatment with piperonyl butoxide, cimetidine, or 3-methylcholanthrene had no effect on hepatic damage by loxistatin. |
1(0,0,0,1) | Details |